Pricing Sign in

DNTH

Dianthus Therapeuticsdistress 5/10 · elevated risk

$103.77+1%today-2% from 52w high

dianthustx.com92 employeesFounded 2019New York, NYBiotechnology

Neurology 1

Lead: generalized myasthenia gravis

Revenue

pre-revenue

Liquidity

$1225M

Runway

9.4 yrs

Shares 1y

+70%

Price & events

+96.7% over 6M

CatalystRating changeDilutionFinancingdashed = today

+1.0%

1D

+8.8%

1W

+18.6%

1M

+15.5%

3M

+98.3%

6M

+369.5%

1Y

+270.9%

2Y

-12.4%

5Y

-15.3%

All

Overview

Market Cap: $5.67B
Volume: 100.66K
52 Week Range: $18.76 – $106
Total Shares: 54.67M
Float Shares: 54.60M
Short %: 20.07%
% Held by Insiders: 0.13%
% Held by Institutions: 121.20%
RVOL: 0.07x
Beta: 0.09

Pipeline stages · 1 programs

Claseprubart

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2028-12

Pipeline · 3 trials · 2 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2028-12 Estimated 50% readout ~2029-02-14	Phase 3	Claseprubart	Myasthenia Gravis, Generalized	—	not yet recruiting
2028-12-31 Estimated 50% readout ~2029-03-16	Phase 3	Claseprubart	Chronic Inflammatory Demyelinating Polyneuropathy	—	recruiting
2026-06-30	Phase 2	Claseprubart	Multifocal Motor Neuropathy	—	recruiting

Catalyst news & presentations · 15

second half of 2028Guided 55%readoutPhase 3claseprubart · Top-line data from Phase 3 gMG trialSEC 8-K
2H 2026Guided 55%readoutPhase 1DNTH212 · Phase 1 healthy volunteer study top-line dataSEC 8-K
2026Guided 40%trial initiationsecondaryPhase 3claseprubart · Phase 3 gMG trial initiationSEC 8-K
Q4 2026Guided 70%readoutPhase 2claseprubart · Top-line data from Phase 2 MoMeNtum trialSEC 8-K
2H’26Guided 55%readoutPhase 2DNTH103 · Top-line Phase 2 results for Multifocal Motor NeuropathySEC 8-K
2026-08-06earningsEarningsEarnings releaseyahoo
mid-2026trial initiationsecondaryPhase 3claseprubart · Phase 3 gMG trial initiationSEC 8-K
mid-2026trial initiationsecondaryPhase 3claseprubart · Phase 3 registrational trial of claseprubart for gMG to initiate.SEC 8-K
Q2 2026readoutPhase 3claseprubart · Phase 3 CIDP interim responder analysisSEC 8-K
2026-03-26fda agreementclaseprubart · FDA agreed to remove ANA screening, remove routine ANA testing, and reclassify SLE risk to DIL for claseprubart trialsSEC 8-K
January 12, 2026conferencedata presentationsecondaryPresentation at 44th Annual J.P. Morgan Healthcare ConferenceSEC 8-K
2H’25readoutPhase 2DNTH103 · Top-line Phase 2 results for generalized Myasthenia GravisSEC 8-K
2025-10-16partnershipDNTH212 · License and Collaboration Agreement with Nanjing Leads Biolabs for exclusive rights outside Greater China to develop, manufacture, and commercialize DNTH212SEC 8-K
September 8, 2025conferencedata presentationsecondaryConference call and webcast to discuss MaGic dataSEC 8-K
September 8, 2025readoutPhase 2claseprubart · Positive top-line data from Phase 2 MaGic trialSEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 54,666,233 · 4 offerings/1y · 0 PIPEs

2026-03-128-Kmaterial_agreement
2026-03-11424B5offering
2026-03-09424B5offering
2026-01-30EFFECTshelf_effective
2026-01-28S-3shelf_registration
2025-10-168-Kmaterial_agreement
2025-09-118-Kmaterial_agreement

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Wall St ratings

strong buy · target $129 (+24% upside) · 12 analysts

2026-05-06WedbushOutperform
2026-04-09Wolfe ResearchOutperform
2026-03-19Wells FargoOverweight
2026-03-12WedbushOutperform
2026-03-10Raymond JamesOutperform → Strong Buy
2026-03-10WedbushOutperform

Competitors — generalized myasthenia gravis

NVSEFNOVARTIS AG$292.0B · D3
AMGNAMGEN INC$195.4B · D3
ARGXARGENX SE$54.3B · D0
IMVTImmunovant, Inc.$7.9B · D2
VORVor Biopharma Inc.$1.0B · D2
CABACabaletta Bio, Inc.$441M · D8
KYTXKyverna Therapeutics, Inc.$439M · D5
RNACCartesian Therapeutics, Inc.$233M · D3
AZNASTRAZENECA PLC— · D3

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.